Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

Title
Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 29, Issue 15_suppl, Pages 7505-7505
Publisher
American Society of Clinical Oncology (ASCO)
Online
2017-02-24
DOI
10.1200/jco.2011.29.15_suppl.7505

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now